<?xml version="1.0" encoding="UTF-8"?>
<p>Targeting the host process during viral infection figures as a promising alternative for drug development and can play an important role in abrogating viral replication (
 <xref rid="B191" ref-type="bibr">Sayce et al., 2010</xref>; 
 <xref rid="B221" ref-type="bibr">Ullah et al., 2019</xref>). Nitazoxanide is a broad-spectrum antiviral agent exploited for the treatment of, for instance, influenza A and B viruses, as well as Ebola virus (EBOV) (
 <xref rid="B184" ref-type="bibr">Rossignol, 2014</xref>; 
 <xref rid="B103" ref-type="bibr">Jasenosky et al., 2019</xref>), with its activity related to the interference in host-regulated pathways during viral replication (
 <xref rid="B185" ref-type="bibr">Rossignol, 2016</xref>). 
 <italic>In vitro</italic> studies demonstrated that Nitazoxanide was able to inhibit MERS-CoV in LLC-MK2 cells, with an EC
 <sub>50</sub> of 0.92 μg mL
 <sup>–1</sup>. The authors suggested that nitazoxanide affects pro-inflammatory cytokines and suppresses their overproduction (
 <xref rid="B185" ref-type="bibr">Rossignol, 2016</xref>).
</p>
